[HTML][HTML] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
[PDF][PDF] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen - scienceopen.com
LNCaP, LNCaP-ENZ48, RES-A, and RES-B samples at the KLK2/KLK3 locus and the
GAPDH locus. The y-axis depicts the average frequency of DNA fragments sequenced from …
GAPDH locus. The y-axis depicts the average frequency of DNA fragments sequenced from …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao… - Nature …, 2021 - mdanderson.elsevierpure.com
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao… - Nature …, 2021 - discovery.ucl.ac.uk
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle… - 2021 - trepo.tuni.fi
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
[PDF][PDF] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle… - 2021 - pure.qub.ac.uk
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
[HTML][HTML] Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle… - Nature …, 2021 - ncbi.nlm.nih.gov
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle… - Nature …, 2021 - ideas.repec.org
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.
S Taavitsainen, N Engedal, S Cao… - Nature …, 2021 - search.ebscohost.com
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse
S Taavitsainen, N Engedal, S Cao, F Handle… - 2021 - bora.uib.no
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …